A citation-based method for searching scientific literature

C Pan, W Yang, J P Barona, Y Wang, M Niggli, P Mohideen, Y Wang, J E Foley. Diabet Med 2008
Times Cited: 124







List of co-cited articles
1002 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
F Xavier Pi-Sunyer, Anja Schweizer, David Mills, Sylvie Dejager. Diabetes Res Clin Pract 2007
248
38

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Emanuele Bosi, Riccardo Paolo Camisasca, Carole Collober, Erika Rochotte, Alan J Garber. Diabetes Care 2007
330
38

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
E Ferrannini, V Fonseca, B Zinman, D Matthews, B Ahrén, S Byiers, Q Shao, S Dejager. Diabetes Obes Metab 2009
212
35

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Julio Rosenstock, Michelle A Baron, Sylvie Dejager, David Mills, Anja Schweizer. Diabetes Care 2007
224
34

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
J Rosenstock, S W Kim, M A Baron, R-P Camisasca, F Cressier, A Couturier, S Dejager. Diabetes Obes Metab 2007
202
34


Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
A J Garber, J E Foley, M A Banerji, P Ebeling, S Gudbjörnsdottir, R-P Camisasca, A Couturier, M A Baron. Diabetes Obes Metab 2008
168
34

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
34




Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Pablo Aschner, Mark S Kipnes, Jared K Lunceford, Matilde Sanchez, Carolyn Mickel, Debora E Williams-Herman. Diabetes Care 2006
637
29

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
W A Scherbaum, A Schweizer, A Mari, P M Nilsson, G Lalanne, S Jauffret, J E Foley. Diabetes Obes Metab 2008
96
29






Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Barry J Goldstein, Mark N Feinglos, Jared K Lunceford, Jeremy Johnson, Debora E Williams-Herman. Diabetes Care 2007
370
23




The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Ralph A DeFronzo, Miguel N Hissa, Alan J Garber, Jorge Luiz Gross, Raina Yuyan Duan, Shoba Ravichandran, Roland S Chen. Diabetes Care 2009
325
22

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Itamar Raz, Yu Chen, Mei Wu, Shehla Hussain, Keith D Kaufman, John M Amatruda, Ronald B Langdon, Peter P Stein, Maria Alba. Curr Med Res Opin 2008
182
21

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
J Rosenstock, C Aguilar-Salinas, E Klein, S Nepal, J List, R Chen. Curr Med Res Opin 2009
237
21


Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Viswanathan Mohan, Wenying Yang, Ho-Young Son, Lei Xu, Liliane Noble, Ronald B Langdon, John M Amatruda, Peter P Stein, Keith D Kaufman. Diabetes Res Clin Pract 2009
110
20

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
441
20


Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
W A Scherbaum, A Schweizer, A Mari, P M Nilsson, G Lalanne, Y Wang, B E Dunning, J E Foley. Diabetes Obes Metab 2008
86
22


Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
B Göke, K Hershon, D Kerr, A Calle Pascual, A Schweizer, J Foley, Q Shao, S Dejager. Horm Metab Res 2008
76
25


Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
D R Matthews, S Dejager, B Ahren, V Fonseca, E Ferrannini, A Couturier, J E Foley, B Zinman. Diabetes Obes Metab 2010
146
19


Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
19


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
18




Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.
Masatoshi Kikuchi, Nobuyuki Abe, Mitsutoshi Kato, Shinji Terao, Nobuyuki Mimori, Hideo Tachibana. Diabetes Res Clin Pract 2009
74
22



Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
L Blonde, S Dagogo-Jack, M A Banerji, R E Pratley, A Marcellari, R Braceras, D Purkayastha, M Baron. Diabetes Obes Metab 2009
40
40



Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
C Pan, X Xing, P Han, S Zheng, J Ma, J Liu, X Lv, J Lu, G Bader. Diabetes Obes Metab 2012
60
26


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.